ATE306936T1 - Faenger fuer oxidantien - Google Patents

Faenger fuer oxidantien

Info

Publication number
ATE306936T1
ATE306936T1 AT96923328T AT96923328T ATE306936T1 AT E306936 T1 ATE306936 T1 AT E306936T1 AT 96923328 T AT96923328 T AT 96923328T AT 96923328 T AT96923328 T AT 96923328T AT E306936 T1 ATE306936 T1 AT E306936T1
Authority
AT
Austria
Prior art keywords
oxidants
catcher
relates
modulating
processes
Prior art date
Application number
AT96923328T
Other languages
English (en)
Inventor
Michael P Trova
James D Crapo
Irwin Fridovich
Tim Oury
Brian J Day
Rodney J Folz
Bruce A Freeman
Ines Batinic-Haberle
Original Assignee
Univ Duke
Univ Alabama Birmingham Res Fo
Aeolus Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/476,866 external-priority patent/US5994339A/en
Application filed by Univ Duke, Univ Alabama Birmingham Res Fo, Aeolus Sciences Inc filed Critical Univ Duke
Application granted granted Critical
Publication of ATE306936T1 publication Critical patent/ATE306936T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96923328T 1995-06-07 1996-06-07 Faenger fuer oxidantien ATE306936T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/476,866 US5994339A (en) 1993-10-15 1995-06-07 Oxidant scavengers
US61341896A 1996-03-11 1996-03-11
PCT/US1996/010497 WO1996040223A1 (en) 1995-06-07 1996-06-07 Oxidant scavengers

Publications (1)

Publication Number Publication Date
ATE306936T1 true ATE306936T1 (de) 2005-11-15

Family

ID=27045322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923328T ATE306936T1 (de) 1995-06-07 1996-06-07 Faenger fuer oxidantien

Country Status (9)

Country Link
EP (1) EP0831891B1 (de)
JP (1) JPH11509180A (de)
AT (1) ATE306936T1 (de)
AU (1) AU725602B2 (de)
CA (1) CA2223407C (de)
DE (1) DE69635304T2 (de)
ES (1) ES2249784T3 (de)
IL (1) IL122451A0 (de)
WO (1) WO1996040223A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5834457A (en) * 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
AU737650B2 (en) * 1997-11-03 2001-08-23 Duke University Substituted porphyrins
DE69928655T2 (de) 1998-04-24 2006-08-24 Duke University Substituierte porphyrine
US6632808B1 (en) 1998-08-11 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of amyloid formation
AU765509B2 (en) 1998-08-28 2003-09-18 Destiny Pharma Limited Porphyrin derivatives, their use in photodynamic therapy and medical devices containing them
ATE552260T1 (de) 1999-01-25 2012-04-15 Nat Jewish Health Substituierte porphyrine und deren therapeutische verwendung
US6403788B1 (en) 2000-07-11 2002-06-11 Eukarion, Inc. Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species
EP1439842A4 (de) 2001-06-01 2009-09-02 Nat Jewish Med & Res Center Oxidantienfänger zur behandlung von diabetes oder zur verwendung bei der transplantation oder induktion von immuntoleranz
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
ITFI20020200A1 (it) * 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L Porfirine meso-sostituite.
US8318803B2 (en) 2003-10-31 2012-11-27 Tae-Yoon Kim EC SOD and use thereof
CN100537602C (zh) * 2003-10-31 2009-09-09 金泰润 Ec sod和细胞转导性ec sod及它们的用途
AU2005231336A1 (en) * 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-Substituted Porphyrin Compounds and methods of use thereof
WO2007038630A2 (en) 2005-09-28 2007-04-05 Inotek Pharmaceuticals Corporation N-benzyl substituted pyridyl porphyrin compounds and methods of use thereof
WO2008114017A2 (en) * 2007-03-19 2008-09-25 Imperial Innovations Limited Compositions and methods relating to influenza infection
US8110402B2 (en) 2008-05-13 2012-02-07 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
JP5608644B2 (ja) 2008-05-23 2014-10-15 ナショナル ジューイッシュ ヘルス アルキル化種の被爆に関連する損傷の処置方法
EP2759546B1 (de) * 2011-09-21 2018-03-21 National University Corporation Okayama University Metallporphyrinkomplex, herstellungsverfahren dafür, seine verwendung als kohlendioxidfixierungskatalysator und verfahren zur herstellung von zyklischen carbonaten
CN102584836B (zh) * 2011-12-31 2014-04-16 中国科学院化学研究所 一种卟啉笼状化合物及其制备方法与应用
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
JP6444211B2 (ja) * 2015-02-24 2018-12-26 学校法人同志社 ポルフィリン誘導体、及びこれを含む光増感剤等
CN105399750B (zh) * 2015-12-11 2018-07-17 西北师范大学 四氮唑卟啉金属配合物及其合成和作为染料敏化剂的应用
CN112694887B (zh) * 2020-12-07 2024-04-26 黑龙江省农业科学院植物保护研究所 一种发光型传感器及其构筑方法与在检测植物水杨酸含量中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3464252D1 (en) * 1983-06-03 1987-07-23 Hoffmann La Roche Labelled molecules for fluorescence immunoassays and processes and intermediates for their preparation
GB8429845D0 (en) * 1984-11-26 1985-01-03 Efamol Ltd Porphyrins & cancer treatment
US5248603A (en) * 1985-09-03 1993-09-28 Symbicom Aktiebolag Superoxide dismutase
US4746735A (en) * 1986-11-21 1988-05-24 The Dow Chemical Company Regiospecific aryl nitration of meso-substituted tetraarylporphyrins
US4892941A (en) * 1987-04-17 1990-01-09 Dolphin David H Porphyrins
US5051337A (en) * 1987-06-10 1991-09-24 Director-General Of Agency Of Industrial Science And Technology Optical recording material
GB8805849D0 (en) * 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
DE3809671A1 (de) * 1988-03-18 1989-09-28 Schering Ag Porphyrin-komplexverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
FR2632187B1 (fr) * 1988-06-02 1990-09-14 Centre Nat Rech Scient Derives de metalloporphyrines, leur preparation, leur application en therapeutique et leur utilisation pour la preparation de molecules hybrides
US5171680A (en) * 1988-06-14 1992-12-15 Chiron Corporation Superoxide dismutase analogs having novel binding properties
DK455789D0 (da) * 1989-09-15 1989-09-15 Symbicom Ab Polypeptid
US5236915A (en) * 1990-05-31 1993-08-17 Health Research, Inc. Meso poly(4-sulfonatophenyl) porphines as MRI image enhancing agents
FR2676738B1 (fr) * 1991-05-22 1995-05-05 Ir2M Nouveau derive organique de metal de transition a structure porphyrinique, composition therapeutique le contenant, en particulier a activite hypoglycemiante.
US5262532A (en) * 1991-07-22 1993-11-16 E.R. Squibb & Sons, Inc. Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants

Also Published As

Publication number Publication date
DE69635304D1 (de) 2006-03-02
AU6387096A (en) 1996-12-30
EP0831891A1 (de) 1998-04-01
EP0831891A4 (de) 1999-02-03
CA2223407C (en) 2011-02-08
DE69635304T2 (de) 2006-07-20
AU725602B2 (en) 2000-10-12
EP0831891B1 (de) 2005-10-19
ES2249784T3 (es) 2006-04-01
CA2223407A1 (en) 1996-12-19
JPH11509180A (ja) 1999-08-17
IL122451A0 (en) 1998-06-15
WO1996040223A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
ATE306936T1 (de) Faenger fuer oxidantien
DE69434313D1 (de) Superoxiddismutase memetika
ATE238307T1 (de) Substituierte porphyrinen
DE69928655D1 (de) Substituierte porphyrine
MXPA01007451A (es) Porfirinas sustituidas.
GB9514451D0 (en) Sustained-release formulation
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
PL320064A1 (en) Application of dioxomorpholines for fighting against endoparasites, novel dioxomorphoines and method of obtaining them
NO2015027I2 (no) Mepolizumab
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
PL343495A1 (en) Heterocyclically substituted amides used as calpain inhibitors
HU9700022D0 (en) Dihydrobenzofuranes
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
NZ503308A (en) Alpha-ketoamide multicatalytic protease inhibitors
DE69831737D1 (de) Neurotrypsin
DE59506532D1 (de) Lutschbonbon mit zahnbelags-neutralisierender wirkung
ZA949564B (en) Method for treating constipation using dimeticone.
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
MX9602767A (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaspiro[4,5]decano-2-propanamina.
MX9804579A (es) Composiciones que contienen bismuto para la prevencion y tratamiento de trastornos gastrointestinales.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831891

Country of ref document: EP